Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
PPAR(Peroxisome proliferator activated receptor) | 1 |
Target |
Mechanism PPAR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDAC inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 14-3-3 protein inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 Feb 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Start Date12 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MHY-2013 ( PPAR ) | Metabolic Diseases More | Preclinical |
SLC-36 | Lung Cancer More | Pending |
MHY-884 ( TYR ) | Sunburn More | Pending |
MHY-218 ( HDACs ) | Neoplasms More | Pending |
HS-1793 ( 14-3-3 protein x HIF-1α ) | Neoplasms More | Pending |